Literature DB >> 17326806

Prevalence of fractures in women with intellectual disabilities: a chart review.

S Schrager1, C Kloss, A W Ju.   

Abstract

BACKGROUND: Numerous studies have demonstrated high rates of osteoporosis and fractures in women with intellectual disabilities (IDs). All of the studies use either institutionalized women or women in the community recruited at adult day-care centres or specialty clinics. We examined the prevalence of fractures in women with IDs who attend a primary care clinic, and assessed osteoporosis-prevention/intervention activities.
METHODS: This was a chart review study. Charts were identified of women with an ICD-9 diagnosis code for ID, Down syndrome or developmental disabilities. All charts reviewed were patients of one of 13 family medicine clinics affiliated with Department of Family Medicine, the University of Wisconsin.
RESULTS: A total of 93 charts were reviewed. More than 32% (30/93) of the charts contained a history of an adult-onset fracture. Increasing age, being postmenopausal and taking anticonvulsant medications were significantly associated with having a fracture. The average age of first fracture was 41.7 years. Of the women with a fracture, 35.5% were placed on a medication to maintain bone density, 67.7% received a recommendation for a calcium supplement, and 38.7% obtained a bone density test. DISCUSSION: The prevalence of fractures in women with IDs attending a family medicine clinic was very high, and fractures occurred at young ages. Primary care providers need to consider women with IDs at a high risk for fractures and begin preventive counselling in young women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17326806     DOI: 10.1111/j.1365-2788.2006.00872.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  10 in total

Review 1.  Aneuploidy and skeletal health.

Authors:  Archana Kamalakar; John R Harris; Kent D McKelvey; Larry J Suva
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

2.  Fracture risk in people with developmental disabilities: results of a large claims data analysis.

Authors:  G Büchele; C Becker; I D Cameron; R Auer; D Rothenbacher; H H König; K Rapp
Journal:  Osteoporos Int       Date:  2016-08-24       Impact factor: 4.507

3.  Low bone mass and impaired fracture healing in mouse models of Trisomy21 (Down syndrome).

Authors:  Kirby M Sherman; Diarra K Williams; Casey A Welsh; Alexis M Cooper; Alyssa Falck; Shannon Huggins; Rihana S Bokhari; Dana Gaddy; Kent D McKelvey; Lindsay A Dawson; Larry J Suva
Journal:  Bone       Date:  2022-06-15       Impact factor: 4.626

Review 4.  Endocrine and musculoskeletal abnormalities in patients with Down syndrome.

Authors:  Yousra Hawli; Mona Nasrallah; Ghada El-Hajj Fuleihan
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

5.  The effect of low-trauma fracture on one-year mortality rate among privately insured adults with and without neurodevelopmental disabilities.

Authors:  Daniel G Whitney; Daniel Whibley; Karl J Jepsen
Journal:  Bone       Date:  2019-09-05       Impact factor: 4.398

Review 6.  Primary care for women with intellectual disabilities.

Authors:  Joanne E Wilkinson; Mary C Cerreto
Journal:  J Am Board Fam Med       Date:  2008 May-Jun       Impact factor: 2.657

7.  Elevated fracture risk for adults with neurodevelopmental disabilities.

Authors:  Daniel G Whitney; Michelle S Caird; Karl J Jepsen; Neil S Kamdar; Christina N Marsack-Topolewski; Edward A Hurvitz; Mark D Peterson
Journal:  Bone       Date:  2019-10-24       Impact factor: 4.398

Review 8.  Emphasizing the health benefits of vitamin D for those with neurodevelopmental disorders and intellectual disabilities.

Authors:  William B Grant; Sunil J Wimalawansa; Michael F Holick; John J Cannell; Pawel Pludowski; Joan M Lappe; Mary Pittaway; Philip May
Journal:  Nutrients       Date:  2015-02-27       Impact factor: 5.717

9.  Racial differences in skeletal fragility but not osteoarthritis among women and men with cerebral palsy.

Authors:  Daniel G Whitney
Journal:  Bone Rep       Date:  2019-07-30

10.  Sclerostin Antibody Treatment Stimulates Bone Formation to Normalize Bone Mass in Male Down Syndrome Mice.

Authors:  Diarra K Williams; Sean G Parham; Eric Schryver; Nisreen S Akel; R Shane Shelton; Jessica Webber; Francis L Swain; Jami Schmidt; Larry J Suva; Dana Gaddy
Journal:  JBMR Plus       Date:  2017-12-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.